[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CN114149427A - Synthesis method of non-neferitone and intermediate thereof - Google Patents

Synthesis method of non-neferitone and intermediate thereof Download PDF

Info

Publication number
CN114149427A
CN114149427A CN202111555792.5A CN202111555792A CN114149427A CN 114149427 A CN114149427 A CN 114149427A CN 202111555792 A CN202111555792 A CN 202111555792A CN 114149427 A CN114149427 A CN 114149427A
Authority
CN
China
Prior art keywords
compound
solvent
acid
prepare
synthesis method
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202111555792.5A
Other languages
Chinese (zh)
Inventor
阮诗文
张薇
严恭超
张鑫鑫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Dingya Pharmaceutical Chemicals Co ltd
Original Assignee
Shanghai Dingya Pharmaceutical Chemicals Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Dingya Pharmaceutical Chemicals Co ltd filed Critical Shanghai Dingya Pharmaceutical Chemicals Co ltd
Priority to CN202111555792.5A priority Critical patent/CN114149427A/en
Publication of CN114149427A publication Critical patent/CN114149427A/en
Priority to PCT/CN2022/139823 priority patent/WO2023109968A2/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

The invention provides a novel synthetic method of a non-neferitone intermediate. The method comprises the following steps: (1) in the presence of acid and in the condition of inert solvent or no solvent, diethyl malonate, 4-cyano-2-methoxybenzaldehyde and 4-amino-5-methyl-2-hydroxypyridine react to prepare a compound 1; (2) carrying out alkylation reaction on the compound 1 obtained in the step (1) and triethyl orthoformate under the catalysis of acid in an inert solvent or in the absence of a solvent to prepare a compound 2; (3) reducing the compound 2 obtained in the step (2) by a reducing agent to prepare a compound 3; (4) in the presence of a catalyst, resolving the compound 3 and alcohol by a chemical method to prepare a chiral compound 4; the reaction formula is shown as follows:

Description

Synthesis method of non-neferitone and intermediate thereof
Technical Field
The invention relates to the field of organic synthesis, in particular to a synthetic method of a non-neferitone intermediate, and further relates to a synthetic method of non-neferitone.
Background
The chemical name of the non-nekinone is (4s) 4- (4-cyano-2-methoxyphenyl) -5-ethoxy-2, 8-dimethyl-1, 4-dihydro-1, 6-naphthyridine-3-formamide, and the structural formula is as follows:
Figure 250622DEST_PATH_IMAGE001
it is a non-steroidal mineralocorticoid receptor antagonist and is used for the treatment of chronic kidney disease.
Patent documents WO2008104306A, CN106795155A, CN101641352A and CN107849043A all report methods for preparing non-naloxone. As can be seen from the above patent applications, many synthesis steps require chiral column resolution, which is expensive, technically time-consuming and labor-consuming, and the solvent consumption is high, resulting in high cost, and is not suitable for industrial production.
Therefore, there is a need to develop a method for preparing pharmaceutically active compounds with high yield, high purity, simplicity, high efficiency, low cost, and easy industrial production, so as to meet the requirements of clinical trials and registration applications. The invention provides a synthesis method of a non-neferitone intermediate, which has the advantages of high yield, simple post-treatment, low cost and easy industrialization, and simultaneously ensures that the product has purity meeting the requirement of registration of raw material medicaments.
Disclosure of Invention
One of the objectives of the present invention is to provide a novel method for synthesizing a non-neferide ketone intermediate, so as to solve the problems of low preparation yield, high cost, complex post-treatment and being not suitable for industrial production in the existing method for synthesizing a non-neferide ketone intermediate.
In order to achieve the above object, the present invention provides, in a first aspect, a novel synthesis method of a non-neferitone intermediate compound 4, comprising the steps of:
(1) in the presence of acid and in the condition of inert solvent or no solvent, diethyl malonate, 4-cyano-2-methoxybenzaldehyde and 4-amino-5-methyl-2-hydroxypyridine react to prepare a compound 1;
(2) carrying out alkylation reaction on the compound 1 obtained in the step (1) and triethyl orthoformate under the catalysis of acid in an inert solvent or in the absence of a solvent to prepare a compound 2;
(3) reducing the compound 2 obtained in the step (2) by a reducing agent to prepare a compound 3;
(4) in the presence of a catalyst, the compound 3 and alcohol are resolved by a chemical method to prepare a chiral compound 4.
The process route is as follows:
Figure 230079DEST_PATH_IMAGE002
。
the second aspect of the present invention also provides a non-neferitone intermediate compound 4, wherein the non-neferitone intermediate compound 4 is prepared by the above synthesis process.
The third aspect of the present invention also provides a novel method for synthesizing non-neferitone, which comprises the following steps: and (3) reacting the compound 4 with ammonia water in a solvent to obtain the non-neferitone I.
The fourth aspect of the present invention also provides the non-neferitone prepared by the synthesis process.
By applying the technical scheme of the invention, the chiral column resolution method is avoided, and the cost is reduced; the chemical method is adopted for splitting, so that the raw material loss is reduced, the post-treatment is simple, and the industrial scale-up production is facilitated.
Detailed Description
It should be noted that the embodiments and features of the embodiments in the present application may be combined with each other without conflict. The present invention will be described in detail with reference to examples.
As described in the background art, the existing synthetic method of non-naloxone has the problems of low preparation yield, high cost, complex post-treatment and being not beneficial to industrial production. In order to solve the above technical problems, the present application provides a novel method for synthesizing non-neferide ketone and its intermediate compound 4, and first, the method for synthesizing the non-neferide ketone intermediate compound 4 comprises the following steps:
(1) in the presence of acid and in the condition of inert solvent or no solvent, diethyl malonate, 4-cyano-2-methoxybenzaldehyde and 4-amino-5-methyl-2-hydroxypyridine react to prepare a compound 1;
(2) carrying out alkylation reaction on the compound 1 obtained in the step (1) and triethyl orthoformate under the catalysis of acid in an inert solvent or in the absence of a solvent to prepare a compound 2;
(3) reducing the compound 2 obtained in the step (2) by a reducing agent to prepare a compound 3;
(4) in the presence of a catalyst, the compound 3 and alcohol are resolved by a chemical method to prepare a chiral compound 4.
The process route is as follows:
Figure 9816DEST_PATH_IMAGE003
。
preferably, the inert solvent in steps (1) and (2) is an alcohol solvent, a halogenated hydrocarbon solvent, an ether solvent, an aromatic hydrocarbon solvent or an amide solvent; the alcohol solvent includes but is not limited to methanol, ethanol, n-propanol, isopropanol, n-butanol or tert-butanol; the halogenated hydrocarbon solvent includes but is not limited to dichloromethane, chloroform, tetrachloromethane, 1, 2-dichloroethane, trichloroethane, tetrachloroethane, chlorobenzene or chlorotoluene; the ether solvent includes but is not limited to diethyl ether, methyl tert-butyl ether, tetrahydrofuran, 1, 4-dioxane; the aromatic hydrocarbon solvents include, but are not limited to, benzene, toluene, xylene, nitrobenzene; the amide solvent includes but is not limited to N, N-dimethylacetamide and N, N-dimethylformamide.
Preferably, the reaction in the step (1) is carried out under the condition of no solvent, and the reaction temperature is room temperature-110 ℃. The acid is acetic acid, trifluoroacetic acid, methane sulfonic acid or p-toluenesulfonic acid, preferably acetic acid.
Preferably, the reaction of step (2) is carried out in the absence of a solvent. The reaction temperature is room temperature-100 ℃. The acid in the step (2) is sulfuric acid, the molar ratio of the sulfuric acid to the compound 1 is 1: 20-1: 5, and the amount of triethyl orthoformate is 5-10 mL/g of the compound 1.
Preferably, the reducing agent in step (3) is any one of sodium borohydride, lithium aluminum tetrahydride, diisobutylaluminum hydride tetrahydrofuran solution, diisobutylaluminum hydride toluene solution, diisobutylaluminum hydride cyclohexane solution, diisobutylaluminum hydride heptane solution, sodium aluminum hydride tetrahydrofuran solution, aluminum hydride, lithium tri-tert-butoxyaluminum hydride tetrahydrofuran solution or sodium bis (2-methoxyethoxy) aluminum hydride toluene solution (60 wt%).
Preferably, the catalyst in step (4) is selected from one or more compounds represented by the following structural formula:
Figure 405026DEST_PATH_IMAGE004
，
Figure 281715DEST_PATH_IMAGE005
，
Figure 104177DEST_PATH_IMAGE006
，
Figure 371211DEST_PATH_IMAGE007
，
Figure 632428DEST_PATH_IMAGE008
，
Figure 301306DEST_PATH_IMAGE009
，
Figure 294670DEST_PATH_IMAGE010
，
Figure 131824DEST_PATH_IMAGE011
，
Figure 868836DEST_PATH_IMAGE012
，
Figure 392221DEST_PATH_IMAGE013
，
Figure 884383DEST_PATH_IMAGE014
，
Figure 126008DEST_PATH_IMAGE015
，
Figure 463449DEST_PATH_IMAGE016
，
Figure 106919DEST_PATH_IMAGE017
，
Figure 442086DEST_PATH_IMAGE018
，
Figure 233324DEST_PATH_IMAGE019
，
Figure 312139DEST_PATH_IMAGE020
。
the molar ratio of the catalyst to the compound 3 is 0.02-0.5: 1.
Preferably, the step (4) further comprises a base and an oxidizing agent, wherein the base is one or more of sodium tert-butoxide, potassium tert-butoxide, cesium carbonate, sodium hydride, potassium carbonate, sodium carbonate, potassium phosphate, 4-dimethylaminopyridine, N-diisopropylethylamine, triethylamine, pyridine, imidazole, tetrabutylammonium fluoride, 2, 6-dimethylpyridine, 1, 8-diazabicyclo [5.4.0] -7-undecene; the molar ratio of the alkali to the compound 3 is 2-5: 1; the oxidant is 4,4' -diphenoquinone, 3, 5-dimethyl-3 ',5' -di-tert-butyl-4, 4' -diphenoquinone, 3, 5-dimethyl-3 ',5' -diisopropyl-4, 4' -diphenoquinone, 3' -dimethyl-5, 5' -di-tert-butyl-diphenoquinone, 3',5,5' -tetra-tert-butyl- [1,1' -bis (cyclohexyl) ] -2,2', one or more of 5,5 '-tetraene-4, 4' -dione or 4- (3, 5-dimethyl-4-oxo-2, 5-cyclohexadien-1-yl) -2, 6-dimethyl-2, 5-cyclohexadien-1-one; the molar ratio of the oxidant to the compound 3 is 0.5-2: 1.
The raw materials and reagents used in the above preparation methods are known compounds in the prior art and are commercially available, and among them, the catalyst described in the step (4) can be prepared by a synthetic method described in, for example, chinese patent application publication No. CN101220039A, etc.
The second aspect of the present invention also provides a non-neferitone intermediate compound 4, wherein the non-neferitone intermediate compound 4 is prepared by the above synthesis process.
The third aspect of the present invention also provides a novel method for synthesizing non-neferitone, which comprises the following steps:
Figure 810116DEST_PATH_IMAGE021
。
the specific synthesis method comprises the following steps: and (3) reacting the compound 4 with ammonia water in a solvent to obtain the non-neferitone I.
Preferably, the solvent is an alcohol, including but not limited to methanol, ethanol, n-propanol, isopropanol, n-butanol, or tert-butanol; the reaction temperature in the step is 0-room temperature, preferably 0-10 ℃, and the reaction time is 10-20 hours, preferably 16-20 hours.
The fourth aspect of the present invention also provides the non-neferitone prepared by the synthesis process.
By applying the technical scheme of the invention, the chiral column resolution method is avoided, and the cost is reduced; the chemical method is adopted for splitting, so that the raw material loss is reduced, the post-treatment is simple, and the industrial scale-up production is facilitated.
EXAMPLE 1 preparation of Compound 1
Figure 644080DEST_PATH_IMAGE022
200mL of acetic acid and 35.2g (0.22mol, 1.1eq) of diethyl malonate are added into a 500mL four-neck flask, after the diethyl malonate is dissolved, 32.2g (0.2mol, 1.0eq) of 4-cyano-2-methoxybenzaldehyde is added, the mixture is stirred for 30 minutes at room temperature, 24.8g (0.2mol, 1.0eq) of 4-amino-5-methyl-2-hydroxypyridine is added, the mixture is reacted for 8 hours at 80 ℃, the reaction progress is monitored by TLC, after the reaction is completed, the reaction liquid drops are added into ice water, the pH value is adjusted to 7-8 by sodium bicarbonate, ethyl acetate is used for extraction, an organic phase is dried and concentrated, and the mixture is pulped by methyl tert-butyl ether to obtain 65.4g of compound 1, the yield is 86.2%, and the purity is 97%.
LC-MS(M+H)+:380.1。
EXAMPLE 2 preparation of Compound 2
Figure 594719DEST_PATH_IMAGE023
Suspending 38g of the compound 1 in 200mL of triethyl orthoformate, heating to 130 ℃, then dropwise adding 5.4mL of concentrated sulfuric acid (2-3 drops per minute) into the reaction system, and stirring overnight at 130 ℃ after dropwise adding. Detecting the reaction is complete, cooling, concentrating the reaction solution to about 50mL, adding 300mL of water, extracting with 500mL of ethyl acetate, drying and concentrating the organic phase, and performing reaction by using n-hexane: ethyl acetate = 10: 1 pulping, purifying, filtering and vacuum drying to obtain 37g of compound 2, with the yield of 91 percent and the purity of 98 percent.
LC-MS(M+H)+:408.2。
EXAMPLE 3 preparation of Compound 3
Figure 477224DEST_PATH_IMAGE024
Under the protection of nitrogen, 150mL of tetrahydrofuran and 20.4g (0.05mol, 1.0eq) of compound 2 are added into a 500mL four-mouth bottle, the reaction solution is cooled to 0 ℃, 2.1g (0.05mol, 1.1eq) of sodium borohydride is added in batches, after the addition is finished, the temperature of the reaction system is controlled to be 45-50 ℃, the reaction is carried out for 2-3 hours, the reaction is detected to be complete by a point plate, diluted hydrochloric acid of 0.5N is used for quenching, the pH value is adjusted to 7-8 by sodium bicarbonate, ethyl acetate is added for extraction, organic coherent concentration is carried out, and the mixed solvent of ethyl acetate/N-hexane =15:1 is used for pulping and purification, so that 15.6g of compound 3 is obtained, the yield is 86%, and the purity is 97%.
LC-MS(M+H)+:364.0。
EXAMPLE 4 preparation of Compound 4
Figure 892025DEST_PATH_IMAGE025
Under nitrogen protection, 15g of Compound 3 (41.3mmol), 6.6g of catalyst cat 7, are introduced into a 500mL four-necked flask
(15mmol), 16.8g of the oxidizing agent 3,5,3',5' -tetra-tert-butyldicyclohexyl-2, 5,2',5' -tetraene-4, 4' -dione (41.3mmol), 150mL of anhydrous dichloromethane, then 9.5g of ethanol (206.5 mmol) and 6.4g N, N-diisopropylethylamine (49.6 mmol) were added, after which the reaction mixture was heated to 40 ℃ overnight, checked for completion by HPLC, then cooled to room temperature, filtered with celite, the filter cake was washed with 200mL of dichloromethane, the filtrate was concentrated at 60 ℃ to remove the solvent, 100mL of ethyl acetate was added to the residue, dissolved by heating to 50 ℃ and then 10mL of N-hexane was added, the mixture was slowly cooled to 10 ℃ (about 6 h), stirred overnight at 10 ℃ and filtered, the filter cake was washed with cold ethyl acetate 3 times to give 13.3g of compound 4, the yield is 79%, the purity is 98%, the ee value is 99.5% (the filling material of the chiral column is selected from poly (N-methacryloyl-D-leucine-dicyclopropylmethylamide), and the mobile phase is ethyl acetate).
LC-MS(M+H)+:408.2。
EXAMPLE 5 preparation of Compound I
Figure 896890DEST_PATH_IMAGE026
Adding 20.4g of compound 4 and 300mL of ethanol into a 1000mL flask, cooling a reaction solution to 0 ℃, then dropwise adding ammonia water (33 percent and 150 mL) into a reaction system, controlling the temperature of the system to be below 5 ℃, continuing to react and stir at the temperature of below 5 ℃ for 16 hours after the addition is finished, separating out solids, detecting that the reaction is complete by using a dot plate, filtering, washing a filter cake by using cold water and ethanol, crystallizing by using ethyl acetate and petroleum ether, stirring the obtained solution for 1 hour, filtering, and drying in a vacuum drying oven at the temperature of 40 ℃ to obtain 16.3g of compound I, wherein the yield is 86.4 percent, the purity is 99.5 percent, and the ee value is 99.4 percent (the filler of a chiral column is selected from poly (N-methacryloyl-D-leucine-dicyclopropylmethylamide), and the mobile phase is 0.5 percent of isopropylamine and ethyl acetate).
LC-MS(M+H)+: 379.0。
1H-NMR (DMSO-d6, 400 MHz) δ: 7.71(s, 1H), 7.54(s, 1H), 7.39-7.37(m, 1H), 7.30-7.27(m, 1H), 7.15-7.13 (m, 1H), 6.79-6.75 (m, 2H), 5.39 (s, 1H), 4.06-4.00 (m, 2H), 3.82 (s, 3H), 2.20 (s, 3H), 2.14(s, 3H), 1.07-1.04 (m, 3H)。
The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention, and various modifications and changes may be made by those skilled in the art. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims (10)

1. A novel synthesis method of a non-neferitone intermediate compound 4, comprising the following steps:
(1) in the presence of acid and in the condition of inert solvent or no solvent, diethyl malonate, 4-cyano-2-methoxybenzaldehyde and 4-amino-5-methyl-2-hydroxypyridine react to prepare a compound 1;
(2) carrying out alkylation reaction on the compound 1 obtained in the step (1) and triethyl orthoformate under the catalysis of acid in an inert solvent or in the absence of a solvent to prepare a compound 2;
(3) reducing the compound 2 obtained in the step (2) by a reducing agent to prepare a compound 3;
(4) in the presence of a catalyst, resolving the compound 3 and alcohol by a chemical method to prepare a chiral compound 4;
the process route is as follows:
Figure 649415DEST_PATH_IMAGE001
。
2. the synthesis method according to claim 1, wherein the reaction in the step (1) is carried out under a solvent-free condition, and the reaction temperature is room temperature to 110 ℃; the acid is acetic acid, trifluoroacetic acid, methane sulfonic acid or p-toluenesulfonic acid, preferably acetic acid.
3. The synthesis method according to claim 1, wherein the reaction in step (2) is carried out in the absence of a solvent; the reaction temperature is room temperature-100 ℃; the acid is sulfuric acid, the molar ratio of the sulfuric acid to the compound 1 is 1: 20-1: 5, and the amount of triethyl orthoformate is 5-10 mL/g of the compound 1.
4. The method according to claim 1, wherein the reducing agent in step (3) is any one of sodium borohydride, lithium aluminum tetrahydride, diisobutylaluminum hydride tetrahydrofuran solution, diisobutylaluminum hydride toluene solution, diisobutylaluminum hydride cyclohexane solution, diisobutylaluminum hydride heptane solution, sodium aluminum hydride tetrahydrofuran solution, aluminum hydride, lithium aluminum tri-tert-butoxyhydride tetrahydrofuran solution or sodium bis (2-methoxyethoxy) aluminum hydride toluene solution (60 wt%).
5. The synthesis method of claim 1, wherein the catalyst in step (4) is selected from one or more compounds represented by the following structural formula:
Figure 70032DEST_PATH_IMAGE002
，
Figure 604918DEST_PATH_IMAGE003
，
Figure 718368DEST_PATH_IMAGE004
，
Figure 705916DEST_PATH_IMAGE005
，
Figure 930223DEST_PATH_IMAGE006
，
Figure 991720DEST_PATH_IMAGE007
，
Figure 341318DEST_PATH_IMAGE008
，
Figure 753845DEST_PATH_IMAGE009
，
Figure 781843DEST_PATH_IMAGE010
，
Figure 25743DEST_PATH_IMAGE011
，
Figure 215416DEST_PATH_IMAGE012
，
Figure 177556DEST_PATH_IMAGE013
，
Figure 743666DEST_PATH_IMAGE014
，
Figure 45335DEST_PATH_IMAGE015
，
Figure 468226DEST_PATH_IMAGE016
，
Figure 855345DEST_PATH_IMAGE017
，
Figure 225146DEST_PATH_IMAGE018
。
6. the synthesis method according to claim 1, wherein the molar ratio of the catalyst in the step (4) to the compound 3 is 0.02-0.5: 1.
7. The method of claim 1, wherein step (4) further comprises a base selected from the group consisting of sodium tert-butoxide, potassium tert-butoxide, cesium carbonate, sodium hydride, potassium carbonate, sodium carbonate, potassium phosphate, 4-dimethylaminopyridine, N-diisopropylethylamine, triethylamine, pyridine, imidazole, tetrabutylammonium fluoride, 2, 6-lutidine, 1, 8-diazabicyclo [5.4.0] -7-undecene; the molar ratio of the alkali to the compound 3 is 2-5: 1.
8. The synthesis method according to claim 1, wherein the step (4) further comprises an oxidizing agent, wherein the oxidizing agent is 4,4' -diphenoquinone, 3, 5-dimethyl-3 ',5' -di-tert-butyl-4, 4' -diphenoquinone, 3, 5-dimethyl-3 ',5' -diisopropyl-4, 4' -diphenoquinone, 3' -dimethyl-5, 5' -di-tert-butyl-diphenoquinone, 3',5,5' -tetra-tert-butyl- [1,1' -bis (cyclohexyl) ] -2,2',5,5' -tetraene-4, 4' -dione or 4- (3, 5-dimethyl-4-oxo-2, 5-cyclohexadien-1-yl) -2, one or more of 6-dimethyl-2, 5-cyclohexadiene-1-one; the molar ratio of the oxidant to the compound 3 is 0.5-2: 1.
9. The synthesis method of the novel non-neferitone comprises the following steps: reacting compound 4 obtained by the synthesis method of claims 1-8 with ammonia water in a solvent to obtain the non-neferitone I.
10. The method of claim 9, wherein the solvent is an alcohol, and the alcoholic solvent includes but is not limited to methanol, ethanol, n-propanol, isopropanol, n-butanol, or t-butanol; the reaction temperature in the step is 0-room temperature, preferably 0-10 ℃, and the reaction time is 10-20 hours, preferably 16-20 hours.
CN202111555792.5A 2021-12-18 2021-12-18 Synthesis method of non-neferitone and intermediate thereof Pending CN114149427A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202111555792.5A CN114149427A (en) 2021-12-18 2021-12-18 Synthesis method of non-neferitone and intermediate thereof
PCT/CN2022/139823 WO2023109968A2 (en) 2021-12-18 2022-12-18 Synthesis method for finerenone and intermediate thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111555792.5A CN114149427A (en) 2021-12-18 2021-12-18 Synthesis method of non-neferitone and intermediate thereof

Publications (1)

Publication Number Publication Date
CN114149427A true CN114149427A (en) 2022-03-08

Family

ID=80451857

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202111555792.5A Pending CN114149427A (en) 2021-12-18 2021-12-18 Synthesis method of non-neferitone and intermediate thereof

Country Status (2)

Country Link
CN (1) CN114149427A (en)
WO (1) WO2023109968A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114524812A (en) * 2022-03-18 2022-05-24 湖南凯铂生物药业有限公司 Crystal form preparation and synthesis method of 1, 4-dihydro-1, 6-naphthyridine compound
CN115322194A (en) * 2022-08-23 2022-11-11 浙江国邦药业有限公司 Method for resolving carboxylic acid of non-neferone intermediate
WO2023109968A3 (en) * 2021-12-18 2023-08-03 上海鼎雅药物化学科技有限公司 Synthesis method for finerenone and intermediate thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101641352A (en) * 2007-02-27 2010-02-03 拜耳先灵制药股份公司 Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
CN104812393A (en) * 2012-05-08 2015-07-29 默沙东公司 Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
CN106795155A (en) * 2014-08-01 2017-05-31 拜耳医药股份有限公司 Prepare the method for the formamide of 2,81,6 naphthyridines of dimethyl Isosorbide-5-Nitrae dihydro of (4S) 4 (methoxyphenyl of 4 cyano group 2) 5 ethyoxyl 3 and its purify for use as active medicine active component
CN106854177A (en) * 2017-01-04 2017-06-16 苏州健雄职业技术学院 A kind of preparation method of the formaldehyde of 6 chlorine, 4 pyridone 3
CN108137587A (en) * 2015-08-21 2018-06-08 拜耳制药股份公司 (4S) -4- (4- cyano -2- methoxyphenyls) -5- ethyoxyls -2 are prepared by electrochemical process, 8- dimethyl -1,4- dihydros -1,6- naphthyridines -3- formamides and recycling (4S) -4- (4- cyano -2- methoxyphenyls) -5- ethyoxyls -2,8- dimethyl -1, the method of 4- dihydro -1,6- naphthyridines -3- formamides
CN110511219A (en) * 2018-05-22 2019-11-29 广东东阳光药业有限公司 The dihydronaphthridine class compound and application thereof that phenyl replaces
CN113214248A (en) * 2021-04-13 2021-08-06 湖南南新制药股份有限公司 1, 4-dihydro-1, 6-naphthyridine derivative, pharmaceutical composition and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8912341B2 (en) * 2013-01-16 2014-12-16 Northwestern University Enantioselective N-heterocyclic carbene-catalyzed annulation reactions with imidazolidinones
CN112174842B (en) * 2020-11-02 2022-04-26 苏州山青竹生物医药有限公司 Method for preparing (S) -3-amino-2-benzyl propionic acid
CN114149427A (en) * 2021-12-18 2022-03-08 上海鼎雅药物化学科技有限公司 Synthesis method of non-neferitone and intermediate thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101641352A (en) * 2007-02-27 2010-02-03 拜耳先灵制药股份公司 Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
CN104812393A (en) * 2012-05-08 2015-07-29 默沙东公司 Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
CN106795155A (en) * 2014-08-01 2017-05-31 拜耳医药股份有限公司 Prepare the method for the formamide of 2,81,6 naphthyridines of dimethyl Isosorbide-5-Nitrae dihydro of (4S) 4 (methoxyphenyl of 4 cyano group 2) 5 ethyoxyl 3 and its purify for use as active medicine active component
CN108137587A (en) * 2015-08-21 2018-06-08 拜耳制药股份公司 (4S) -4- (4- cyano -2- methoxyphenyls) -5- ethyoxyls -2 are prepared by electrochemical process, 8- dimethyl -1,4- dihydros -1,6- naphthyridines -3- formamides and recycling (4S) -4- (4- cyano -2- methoxyphenyls) -5- ethyoxyls -2,8- dimethyl -1, the method of 4- dihydro -1,6- naphthyridines -3- formamides
CN106854177A (en) * 2017-01-04 2017-06-16 苏州健雄职业技术学院 A kind of preparation method of the formaldehyde of 6 chlorine, 4 pyridone 3
CN110511219A (en) * 2018-05-22 2019-11-29 广东东阳光药业有限公司 The dihydronaphthridine class compound and application thereof that phenyl replaces
CN113214248A (en) * 2021-04-13 2021-08-06 湖南南新制药股份有限公司 1, 4-dihydro-1, 6-naphthyridine derivative, pharmaceutical composition and application thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GRAZIANO DI CARMINE ET AL.: "Enantioselective Desymmetrization of 1,4-Dihydropyridines by Oxidative NHC Catalysis", 《CHEM. EUR. J.》, vol. 25, pages 7469 - 7474, XP071849581, DOI: 10.1002/chem.201901243 *
JAMES MCNULTY ET AL.: "A scalable process for the synthesis of (E)-pterostilbene involving aqueous Wittig olefination chemistry", 《TETRAHEDRON LETTERS》, vol. 54, pages 6303 - 6306, XP028754632, DOI: 10.1016/j.tetlet.2013.09.019 *
危彬等: "硼氢化钠在水中对羟基(羰基)酯的还原反应研究", 《河南师范大学学报（自然科学版）》, vol. 40, no. 3, pages 82 - 84 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023109968A3 (en) * 2021-12-18 2023-08-03 上海鼎雅药物化学科技有限公司 Synthesis method for finerenone and intermediate thereof
CN114524812A (en) * 2022-03-18 2022-05-24 湖南凯铂生物药业有限公司 Crystal form preparation and synthesis method of 1, 4-dihydro-1, 6-naphthyridine compound
CN115322194A (en) * 2022-08-23 2022-11-11 浙江国邦药业有限公司 Method for resolving carboxylic acid of non-neferone intermediate
CN115322194B (en) * 2022-08-23 2024-04-09 浙江国邦药业有限公司 Method for resolving carboxylic acid of non-neridone intermediate

Also Published As

Publication number Publication date
WO2023109968A2 (en) 2023-06-22
WO2023109968A3 (en) 2023-08-03

Similar Documents

Publication Publication Date Title
CN114149427A (en) Synthesis method of non-neferitone and intermediate thereof
CN109942576B (en) Irbinitinib and preparation method of intermediate
CN106831737B (en) Preparation of vipatavir and derivatives thereof
CN103408502B (en) Synthetic method of quinazolinone compounds
WO2023034786A1 (en) Process for synthesizing naphthyridine derivatives and intermediates thereof
CN110483549B (en) Preparation method of nitroimidazole pyran antituberculosis drug
WO2005044805A1 (en) A novel process for preparing donepezil and its derivatives
CN109748902B (en) Preparation method of erlotinib hydrochloride
CN102863371A (en) Fluoro dihydropyrrole or fluoro pyrrole
CN114539088B (en) Preparation method of oseltamivir
CN109134351B (en) Synthesis method of S-3- (4-aminophenyl) piperidine
CN115677636A (en) Preparation method of 2, 3',4' -biphenyl tetracarboxylic dianhydride
CN116041253A (en) Method for synthesizing diphenyl-2-pyridylmethane derivative
CN114349686B (en) 1, 4-dihydropyridine chiral hybrid hydrogenation reagent, preparation method and application thereof
CN115197228A (en) Synthesis method of pyrazolone [ spiro ] dihydrophthalazine and 1,3-indenedione [ spiro ] dihydrophthalazine compounds
CN114014864A (en) Preparation process of traasiril compound
CN112679431B (en) Method for preparing isoquinolinones compound
CN111138355A (en) Preparation method of formaldehyde-substituted aza-condensed ring compound
JPH0570434A (en) Production of novel 2-hydroxymethyl-4-methoxy-3,5-dimethylpyridine and its intermediate and their production
CN107531662B (en) Synthesis method of nebivolol and intermediate compound thereof
CN112979529B (en) Aromatic amine indole naphthoquinone derivative and preparation method thereof
CN114644636B (en) Method for preparing tofacitinib key intermediate
CN114805168B (en) Pyrrolinones and synthesis method thereof
CN109384734B (en) Preparation method of Selsemipa intermediate
WO2007074686A1 (en) Method for producing optically active n-(3-halo-2-hydroxypropyl)phthalimide

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220308